News | EP Lab | May 18, 2018

Myocarditis is an Under-recognized Etiology of Symptomatic Premature Ventricular Arrhythmia

Findings of the MAVERIC Registry presented at the Heart Rhythm 2018

Myocarditis is an Under-recognized Etiology of Symptomatic Premature Ventricular Arrhythmia (PVCs). #HRS #HRS2018

May 18, 2018 — A significant number of patients with symptomatic premature ventricular contractions (PVCs) have underlying myocarditis identified by FDG-PET, and treatment with immunosuppressive therapy may significantly impact outcomes. This was a key finding in a review of the Myocarditis and Ventricular Arrhythmia (MAVERIC) Registry presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions. 

Symptomatic premature ventricular contractions (PVCs) are common in clinical practice. Myocarditis often goes unrecognized with a potential for continued disease progression & cardiomyopathy. PVCs may be marker of underlying myocarditis; identification and Rx of myocarditis may improve outcomes.

The registry data includes 107 patients with symptomatic PVCs and no underlying ischemic heart disease (IHD). These patients had viral and autonomic serology, 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), cardiac magnetic resonance imaging (CMR) and myocardial biopsy. Patients with focally positive PET scans were labelled as mycarditis and were treated with immunosuppressive therapy (IST) as first line therapy, followed by ablation as needed. Response to therapy was assessed by repeat PET scan and Holter monitor at three-monthly intervals. Optimal clinical response was defined as greater than 80 percent decline in PVC burden and resolution of uptake on PET scans. Suboptimal response was defined as less than 80 percent decrease in ventricular arrhythmia burden on cardiac monitoring with lack of PET resolution.

The cohort was composed of 41 percent men with 57±15 years and 47±11.8 percent left ejection fraction (LVEF). Myocarditis was seen in 51 percent (55/107) of PET scans. Cardiac MRI was correlative of PET in 27.4 percent of patients. In 47 percent of patients, PVC site of origin correlated with site of inflammation (maximal intensity). IST was started in 83.6 percent (46/55) of PET positive patients. There were 32 patients (69.5 percent) who received IST alone and 14 (30.5 percent) underwent IST and catheter ablation. 

Optimal response was seen in 76 percent (29/38) and suboptimal response was seen in 24 percent (9/38) over a mean follow up of 6±3 months. The data show 37 percent of patients who had left ventricular dysfunction ejection fraction (EF) improved (Δ13 ± 6 percent). Lymphocytic infiltrative myocarditis was the most common pathologic finding (46 percent, 13/28), biological markers were not diagnostic. Of the untreated patients, 67 percent (4/6) had worsening EF (Δ10 ± 4 percent) over six months of follow up.

Researchers said a randomized, control trial should be undertaken to assess the impact of IST in patients with PVCs and myocarditis. They said this would help better understand the etiopathogenesis and therapy strategies.

Find links to all the Heart Rhythm 2018 Late-breaking Studies

 

 

#HRS2018 #HRS18

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init